ストックスクリーナーアプリを入手
1.00
14.35%
-0.1675
Brainstorm Cell Therapeutics Inc (BCLI) 最新ニュース
Brainstorm Cell Therapeutics Stock Price Forecast. Should You Buy BCLI? - StockInvest.us
BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions - Yahoo Finance
Brainstorm Cell Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pitts Peter Joe - Moomoo
BrainStorm Cash Drops to $0.2 Million, Raising Going-Concern Risk - Minichart
Brainstorm Cell Therapeutics (BCLI) posts loss and warns on going concern - Stock Titan
BCLI: Phase 3b ALS trial preparations advance as net loss widens and new capital is secured - TradingView
BrainStorm Posts $3.9 Million Second-Quarter Net Loss as NurOwn Trial Preparations Continue - Quiver Quantitative
Brainstorm Cell Therapeutics | 8-K: BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
Lunai Bioworks signs collaboration with BrainStorm Therapeutics By Investing.com - Investing.com South Africa
Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027 - PR Newswire
Brainstorm Appoints Former FDA Associate Comm - Moomoo
BrainStorm Cell Reshapes Leadership to Advance NurOwn Trial - TipRanks
Form 4 Brainstorm Cell Therapeutics Inc For: 28 July By Investing.com - Investing.com Nigeria
BrainStorm Cell (BCLI) grants 100,000 RSUs to director Frenkel - Stock Titan
Brainstorm Cell Therapeutics Inc. Announces Executive and Board Changes - marketscreener.com
BrainStorm names ex-FDA official Pitts as executive chairman By Investing.com - Investing.com Canada
BrainStorm's ALS Trial Set to Launch Under First-Ever Special Protocol Assessment - Stock Titan
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman - Prime Publishers, Inc.
CYVNY Stock Price and Chart — OTC:CYVNY - TradingView
Peter Joe Pitts Net Worth (2026) - GuruFocus
Price to earnings forward of BrainStorm Cell Therapeutics Inc. – OTC:BCLI - TradingView
Price to earnings forward of Brainstorm Cell Therapeutics Inc. – SWB:GHD - TradingView
Brainstorm Cell Therapeutics (BCLI) Status Update Summary - Quartr
Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK - Barchart.com
Brainstorm Cell Therapeutics Inc. Actuals & Estimates (OTC:BCLI) - TradingView
Brainstorm Cell Therapeutics Inc (BCLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Institutional Confidence - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Brainstorm Cell Therapeutics Inc - TradingKey
BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down - MSN
Brainstorm leaders urge FDA to update treatment review process - ALS News Today
BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. (BCLI) Stock Price, Quote, News & History - Benzinga
Gene and Cell Therapies Targeting CNS Disorders Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Brainstorm Cell Therapeutics, MeiraGTx, Voyager Thera - Barchart.com
The Escalator: VML Health, BrainStorm Cell Therapeutics, Syneos Health and more - Medical Marketing and Media
Brainstorm Cell (BCLI) director discloses 150,000-share stock option grant - Stock Titan
[EFFECT] BRAINSTORM CELL THERAPEUTICS INC. SEC Filing - Stock Titan
BrainStorm Cell Therapeutics Announces Publication Calling for U - GuruFocus
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine - PR Newswire
BrainStorm (BCLI) CEO granted 1.8M restricted stock units as equity pay - Stock Titan
BrainStorm Cell (BCLI) EVP Uri Yablonka awarded 150,000 RSUs in new grant - Stock Titan
Officer at Brainstorm Cell (NASDAQ: BCLI) awarded 100,000 RSUs - Stock Titan
BrainStorm Cell (NASDAQ: BCLI) director receives 200,000 RSUs as stock award - Stock Titan
Brainstorm Cell (BCLI) director receives 120,000-share RSU award - Stock Titan
BrainStorm Cell Therapeutics Inc. Appoints Peter J. Pitts to Board of Directors, Effective May 29, 2026 - marketscreener.com
Gene and Cell Therapies Targeting CNS Disorders Market - openPR.com
BrainStorm Adds Former FDA Leader to Board - TipRanks
Peter Pitts joins Brainstorm Cell (OTCQB: BCLI) board of directors - Stock Titan
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commi - GuruFocus
BrainStorm adds ex-FDA official to board ahead of ALS trial By Investing.com - Investing.com South Africa
BrainStorm adds ex-FDA official to board ahead of ALS trial - Investing.com Australia
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors - PR Newswire
BCLI SEC FilingsBrainstorm Cell Therapeutics I 10-K, 10-Q, 8-K Forms - Stock Titan
7.8M Brainstorm (OTCQB: BCLI) shares registered for warrant-linked resale - Stock Titan
Brainstorm Cell Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
BrainStorm Cell (BCLI) director receives 150,000 stock options at $0.70 strike - Stock Titan
BrainStorm Cell (BCLI) director granted 150K options at $0.70 strike - Stock Titan
1.48%
0.31%
大文字化:
|
ボリューム (24 時間):